◆ 会议时间：2025年5月4-7日
◆ 会议地点：英国 格拉斯哥

◆ 会议简介：

2025年第93届欧洲动脉粥样硬化学会(EAS)大会（年会）将于2025年5月4-7日在英国格拉斯哥举行，会议由欧洲动脉粥样硬化学会(EAS)组织。

欧洲动脉硬化学会(EAS)成立于1964年，其宗旨是促进和交流有关动脉粥样硬化疾病的病因、自然史、治疗和预防的知识。50多年来，EAS的专业知识已经被用来教授临床医生如何管理管理血脂紊乱和如何预防动脉粥样硬化，通过向其成员提供教育材料与参加大会和课程的机会，以及提供一个可以讨论最新进展的论坛，EAS有助于宣该领域知识的发展，并最终改善心血管疾病和脂质紊乱患者的治疗。EAS每年在欧洲不同的城市组织一次为期3天的科学会议，约有2500名对心血管疾病感兴趣的基础和临床科学家、临床医生与行业从业者参加EAS大会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

EAS 2025 - 93rd European Atherosclerosis Society (EAS) Congress

Date: May 4-7, 2025
Venue: Glasgow, UK

以下为上届会议信息

摘要征文投稿：

Abstract submission Deadline: December 5, 2023 (midnight CET)

Notifications to submitters will be emailed by mid-February, 2024.

Late Breaking abstract submission will be between 11-26 March, 2024.A late-breaking abstract submission is not an extension to the regular submission, but this abstract should contain new information with results that were not yet known\fully available on the regular abstract submission deadline.

Click here to submit your abstract

EAS Embargo Policy:

The findings described in an abstract submitted for presentation must contain some new data.  The abstract, in its entirety, may not have been published, presented elsewhere, or otherwise publicly discussed prior to their presentation at the EAS Congress.​

Rules for Submission:

• The presenting author is expected to attend the congress and present the poster or oral presentation.
• The presenting author is required to ensure that all co-authors are aware of and approve the content of the abstract before submission.
• There is no limit to the number of abstracts an author can submit. However, authors can only be presenting author of one abstract.
• All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university scientific publications office (or other similar facility) or by a copy editor, prior to submission.

Guidelines

Participants interested in making an oral or poster presentation are invited to submit an abstract. All abstracts will undergo review by the Abstract Review Committee, to determine which abstracts may be accepted. To submit your abstract you will first need to register contact details according to the information below on “Writing & submitting your abstract”.

For questions about the submission, please contact: eas_abstracts@kenes.com

Accepted abstracts will be invited for presentation in one of the following formats:

• Oral presentation
• Poster Discussion a science at a glance session
• Poster viewing in the poster gallery

Abstract submission and presentation rules

Submission

• All abstracts submitted via the online submission form before the deadline will be forwarded to the Abstract Review Committee for review.
• The first author cannot submit more than one abstract
• All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university scientific publications office (or other similar facility) or by a copy editor, prior to submission.
• Abstracts submitted by fax or e-mail will not be accepted.
• Please do not submit multiple copies of the same abstract.

Late Breaking abstract

These abstracts must include new decisive and original results obtained after the submission dead line of december. This apply to clinical trials, breakthroughs in fundamental research. The justification of the late breaking  must be added as a commentary upon submission

The review committee may reject the abstract in case of lack of originality or absence of justification of the delayed submission

Confirmation of receipt & notification of decision

• You will receive email confirmation that your abstract has been received, indicating the abstract number which it has been allocated. Please refer to this abstract number in all correspondence regarding the abstract.
• Please contact the Secretariat if you submit an abstract and do not receive confirmation that it has been received.
• Notifications regarding status of your abstract will be sent once the review process is complete.

Presentation at Congress

• Instructions for preparation of oral or poster presentations will be sent together with acceptance notifications.
• The Committee will endeavour to schedule abstracts according to authors’ preferences but reserves the right to decide on the final form of presentation.
• For each abstract, an author is expected to attend the congress and make the poster or oral presentation. Presenting authors must register by March 13, 2024.
• All accepted and presented abstracts for which a presenting author is registered and has paid the registration fee by the deadline:
  – will be scheduled for presentation and included in the online Congress Scientific Programme.
  – will be included in the Congress proceedings in the Society’s journal, Atherosclerosis, in an issue to be published 3 months after the Congress.
• Abstracts for which no author has registered to attend Congress by March 13, 2024 will not be included in the final Congress Scientific Programme.

Writing & submitting your abstract

Please follow the guidance below when writing and submitting your abstract. Failure to do so may result in your abstract receiving a low grade making it unsuitable for further consideration.

• The abstract should be as informative as possible
• Aim: state background and specific objective of study
• Methods: shortly describe methods used including
  • Design and setting of the study, clear description of interventions and comparisons
  • Human studies: characteristics of participants, including number, diagnosis, sex, and ethnicity as appropriate
  • Animal studies: report number of animals, species, strain, and genotype if relevant
  • Other studies: clear description of materials, such as cell lines and conditions
  • Type of statistical analyses used
• Results: summarize results obtained, report quantitative data, confidence intervals, and p values for comparisons
• Conclusions: state conclusions reached
• Standard abbreviations may be used.

Before you begin, please prepare the following information:

• Presenting author’s contact details:  
• Email address
• Full postal address
• Phone number
• Date of birth

Presentation type – please choose from one of the following:

• Oral presentation
• Poster presentation
• Science at a Glance Presentation (SaaG Poster)

Author and co-authors’ details:

• Full first and family name(s)
• Affiliation details: department, institution / hospital, city, state (if relevant), country

Abstract title – Limited to 25 words in Sentence Structure and including the study design if appropriate

Abstract text – Limited to 300words (Please Note: Word count is not affected when graphs/tables/images are added).

Abstract topic – Abstracts must be allocated to a specific topic for the Scientific Program. Please choose from the list of topics.

Abstract may be reallocated by the scientific committee, in order to organize consistent sessions

Diagrams/Table/Images

• Prepare all images in JPG format before starting the process.
• If you wish to add more than one image/table/graphics, you must prepare a single JPG file and this should not exceed 200 Kbytes.
• The Organizing Secretariat will check all images and can decide to change their dimensions or reject them according to the publisher.

Declaration of Consent to Publication and Assignation of Copyright

• I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
• Submission of the abstract constitutes my consent to publication (e.g. congress website, programmes, other promotions, etc.)
• The Abstract Submitter warrants and represents that he/she is the sole owner or has the rights of all the information and content (“Content”) provided to EAS 2024 and Kenes International (Hereafter: “The Organisers”). The publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property rights.
• The Abstract Submitter grants the Organisers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the Content. 
• The Organisers reserve the right to remove from any publication an
  abstract which does not comply with the above.
• I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.

On behalf of the European Atherosclerosis Society (EAS) and the New French Society of Atherosclerosis we are proud to invite you to participate in the 92nd EAS Congress in the city of Lyon. Lyon, the capital of the Gauls during the Roman Empire, is recognised for its cuisine and gastronomy as well architectural landmarks (UNESCO World Heritage Centre). Today Lyon is a major economic hub and is the second-largest student city in France.

The congress will carry on from the successful recent congress held in Mannheim, Germany and will offer in-person and virtual attendance. During the meeting we will explore the latest developments in basic, translational and clinical research into the causes of atherosclerosis and related vascular disease, and how these may affect the clinical guidelines for diagnosis and treatment. One of the key features of our Congress is the high-level interdisciplinary exchange between clinicians and basic researchers. With many world-leading experts already confirmed, the EAS 2024 scientific programme will offer an overview of the latest current research in the field – including the award-winning Anitschkow Lecture, outstanding Keynote Lectures, state-of-the-art Plenary Sessions, and focused Workshops and Advance Clinical Seminars. We firmly believe that the personal meeting – presenting and discussing one’s work with others and sparking ideas from others’ work – is the key to progress in science. We encourage you to join us – to ask questions and share ideas during the Science at a Glance and Poster Sessions.

The EAS mission is also to support young scientists in progressing their careers through Young Investigator Fellowships. This important initiative offers early-career scientists the opportunity to take part in the Congress, to learn through presenting their own research, attending the scientific programme, and getting to know others in the field. Information about Fellowships can be found on the Society website, and we welcome abstract submissions from young scientists.

We are extremely happy to invite you to attend the EAS 2024 Congress in Lyon, on May 26 – May 29. You are sure to gain new friends, new ideas, and inspiration to take your studies of atherosclerosis and related vascular disease to new levels!

Philippe Moulin
Congress Chair & Co-Chair Scientific Programme Committee

Marianne Benn
Co-Chair Scientific Programme Committee

Stefano Romeo
Co-Chair Scientific Programme Committee

Kausik Ray
EAS President

◆ 参会对象：医生、药剂师、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。